Novartis is running out of options in its bid to defend oral muscular sclerosis therapy Gilenya from early generic competition in the US. The US Court of Appeals for the Federal Circuit (CAFC) has ...
As the US and Europe experiences shortages of crucial medicines, Ben Hargreaves looks at how a once thriving generics industry is now struggling, with many companies seeking to exit the space. Generic ...
In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback